CA3167052A1 - Vaccines and uses thereof to induce an immune response to sars-cov2 - Google Patents
Vaccines and uses thereof to induce an immune response to sars-cov2 Download PDFInfo
- Publication number
- CA3167052A1 CA3167052A1 CA3167052A CA3167052A CA3167052A1 CA 3167052 A1 CA3167052 A1 CA 3167052A1 CA 3167052 A CA3167052 A CA 3167052A CA 3167052 A CA3167052 A CA 3167052A CA 3167052 A1 CA3167052 A1 CA 3167052A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- rmva
- acid sequence
- seq
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims description 64
- 230000028993 immune response Effects 0.000 title description 8
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 691
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 181
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 181
- 206010046865 Vaccinia virus infection Diseases 0.000 claims abstract description 146
- 208000007089 vaccinia Diseases 0.000 claims abstract description 146
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 129
- 239000013603 viral vector Substances 0.000 claims abstract description 88
- 238000002255 vaccination Methods 0.000 claims abstract description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 488
- 101710139375 Corneodesmosin Proteins 0.000 claims description 352
- 102100031673 Corneodesmosin Human genes 0.000 claims description 351
- 108090000623 proteins and genes Proteins 0.000 claims description 318
- 102000004169 proteins and genes Human genes 0.000 claims description 268
- 101710085938 Matrix protein Proteins 0.000 claims description 206
- 101710127721 Membrane protein Proteins 0.000 claims description 206
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 198
- 150000001413 amino acids Chemical class 0.000 claims description 198
- 101710204837 Envelope small membrane protein Proteins 0.000 claims description 170
- 101710145006 Lysis protein Proteins 0.000 claims description 170
- 102000003886 Glycoproteins Human genes 0.000 claims description 144
- 108090000288 Glycoproteins Proteins 0.000 claims description 144
- 241001678559 COVID-19 virus Species 0.000 claims description 130
- 238000006467 substitution reaction Methods 0.000 claims description 124
- 241001115401 Marburgvirus Species 0.000 claims description 97
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 94
- 230000004927 fusion Effects 0.000 claims description 92
- 108060003393 Granulin Proteins 0.000 claims description 53
- 102220599406 Spindlin-1_N501Y_mutation Human genes 0.000 claims description 44
- 241000700605 Viruses Species 0.000 claims description 44
- 102000005962 receptors Human genes 0.000 claims description 26
- 108020003175 receptors Proteins 0.000 claims description 26
- 102220599656 Spindlin-1_E484K_mutation Human genes 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 17
- 102220590605 Spindlin-1_K417T_mutation Human genes 0.000 claims description 14
- 208000025721 COVID-19 Diseases 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 101150036892 VP40 gene Proteins 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 229940022962 COVID-19 vaccine Drugs 0.000 claims description 10
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 10
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 8
- 102220590604 Spindlin-1_K417N_mutation Human genes 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 229940026207 Moderna COVID-19 vaccine Drugs 0.000 claims description 4
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229960000074 biopharmaceutical Drugs 0.000 claims description 4
- 229940023041 peptide vaccine Drugs 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 108010041986 DNA Vaccines Proteins 0.000 claims description 3
- 229940021995 DNA vaccine Drugs 0.000 claims description 3
- 229940021704 adenovirus vaccine Drugs 0.000 claims description 3
- -1 or variant thereof Proteins 0.000 claims description 3
- 108700022172 2019-nCoV Vaccine mRNA-1273 Proteins 0.000 claims description 2
- 229940025280 BBV152 vaccine Drugs 0.000 claims description 2
- 229940125606 CureVac COVID-19 vaccine Drugs 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 229940125621 EpiVacCorona Drugs 0.000 claims description 2
- 229940026205 Gam-COVID-Vac Drugs 0.000 claims description 2
- 229940024452 Janssen COVID-19 vaccine Drugs 0.000 claims description 2
- 241000219823 Medicago Species 0.000 claims description 2
- 229940125597 SCB-2019 Drugs 0.000 claims description 2
- 229940125574 Sinopharm COVID-19 vaccine Drugs 0.000 claims description 2
- 229940025291 Sinovac-CoronaVac COVID-19 vaccine Drugs 0.000 claims description 2
- 229940125611 ZyCoV-D Drugs 0.000 claims description 2
- 229940124590 live attenuated vaccine Drugs 0.000 claims description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 claims description 2
- 229940038694 mRNA-based vaccine Drugs 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims description 2
- 238000012827 research and development Methods 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 108010033276 Peptide Fragments Proteins 0.000 claims 4
- 102000007079 Peptide Fragments Human genes 0.000 claims 4
- 102100021696 Syncytin-1 Human genes 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 39
- 239000012634 fragment Substances 0.000 abstract description 33
- 239000000203 mixture Substances 0.000 abstract description 15
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 abstract description 13
- 230000036039 immunity Effects 0.000 abstract description 10
- 230000001939 inductive effect Effects 0.000 abstract description 7
- 230000001681 protective effect Effects 0.000 abstract description 4
- 230000037452 priming Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 255
- 235000001014 amino acid Nutrition 0.000 description 202
- 229940024606 amino acid Drugs 0.000 description 168
- 108020001507 fusion proteins Proteins 0.000 description 163
- 102000037865 fusion proteins Human genes 0.000 description 161
- 108091026890 Coding region Proteins 0.000 description 157
- 108091081024 Start codon Proteins 0.000 description 130
- 108020004705 Codon Proteins 0.000 description 106
- 230000014621 translational initiation Effects 0.000 description 100
- 230000001105 regulatory effect Effects 0.000 description 74
- 241000711573 Coronaviridae Species 0.000 description 59
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 56
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 35
- 102220277108 rs1553412687 Human genes 0.000 description 35
- 102200056390 rs12204826 Human genes 0.000 description 34
- 238000012217 deletion Methods 0.000 description 31
- 230000037430 deletion Effects 0.000 description 31
- 108700002673 Coronavirus M Proteins Proteins 0.000 description 30
- 239000002773 nucleotide Substances 0.000 description 30
- 125000003729 nucleotide group Chemical group 0.000 description 30
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 30
- 239000000427 antigen Substances 0.000 description 29
- 108091007433 antigens Proteins 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 239000002253 acid Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 22
- 125000000539 amino acid group Chemical group 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 21
- 241000700618 Vaccinia virus Species 0.000 description 20
- 230000024932 T cell mediated immunity Effects 0.000 description 19
- 101710186180 Matrix protein VP40 Proteins 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 210000004899 c-terminal region Anatomy 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 230000035772 mutation Effects 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 101800001055 Truncated S protein Proteins 0.000 description 12
- 241000315672 SARS coronavirus Species 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 102220579649 ATP-dependent RNA helicase A_K417N_mutation Human genes 0.000 description 10
- 125000006850 spacer group Chemical group 0.000 description 10
- OVKKNJPJQKTXIT-JLNKQSITSA-N (5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO OVKKNJPJQKTXIT-JLNKQSITSA-N 0.000 description 9
- 229940096437 Protein S Drugs 0.000 description 9
- 101710198474 Spike protein Proteins 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 230000007775 late Effects 0.000 description 9
- 108091035707 Consensus sequence Proteins 0.000 description 8
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000013605 shuttle vector Substances 0.000 description 7
- 239000013638 trimer Substances 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 6
- 102220599672 Spindlin-1_D614G_mutation Human genes 0.000 description 6
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 6
- 102220599611 Spindlin-1_T716I_mutation Human genes 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000028996 humoral immune response Effects 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 102220053106 rs199537178 Human genes 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 101710172711 Structural protein Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000013504 emergency use authorization Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102220206935 rs1057523452 Human genes 0.000 description 5
- 102220077512 rs797044926 Human genes 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 101000953880 Severe acute respiratory syndrome coronavirus 2 Membrane protein Proteins 0.000 description 4
- 102220590628 Spindlin-1_L18F_mutation Human genes 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000008348 humoral response Effects 0.000 description 4
- 102220159948 rs200073988 Human genes 0.000 description 4
- 102220030033 rs398123766 Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102220585969 Claspin_S982A_mutation Human genes 0.000 description 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 3
- 102220518444 Enhancer of filamentation 1_T29I_mutation Human genes 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 244000309467 Human Coronavirus Species 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 101150108558 PAD1 gene Proteins 0.000 description 3
- 102220554681 Putative uncharacterized protein ZNF252P-AS1_L84I_mutation Human genes 0.000 description 3
- 101000667982 Severe acute respiratory syndrome coronavirus 2 Envelope small membrane protein Proteins 0.000 description 3
- 102220592182 Spindlin-1_A222V_mutation Human genes 0.000 description 3
- 102220599680 Spindlin-1_A570D_mutation Human genes 0.000 description 3
- 102220599400 Spindlin-1_D1118H_mutation Human genes 0.000 description 3
- 102220592185 Spindlin-1_D215G_mutation Human genes 0.000 description 3
- 102220590548 Spindlin-1_D253G_mutation Human genes 0.000 description 3
- 102220590696 Spindlin-1_G142D_mutation Human genes 0.000 description 3
- 102220599673 Spindlin-1_H655Y_mutation Human genes 0.000 description 3
- 102220599610 Spindlin-1_P681H_mutation Human genes 0.000 description 3
- 102220599614 Spindlin-1_Q677H_mutation Human genes 0.000 description 3
- 102220599635 Spindlin-1_S982A_mutation Human genes 0.000 description 3
- 102220590684 Spindlin-1_T95I_mutation Human genes 0.000 description 3
- 102220599410 Spindlin-1_V483A_mutation Human genes 0.000 description 3
- 102220599416 Spindlin-1_Y453F_mutation Human genes 0.000 description 3
- 102220510809 Toll-like receptor 3_P681H_mutation Human genes 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 102220251909 rs1555494636 Human genes 0.000 description 3
- 102200088972 rs1801133 Human genes 0.000 description 3
- 102200118205 rs33990858 Human genes 0.000 description 3
- 102220081228 rs372168541 Human genes 0.000 description 3
- 102220075059 rs529697285 Human genes 0.000 description 3
- 102200069083 rs55826713 Human genes 0.000 description 3
- 102220106470 rs569543350 Human genes 0.000 description 3
- 102220046286 rs587782805 Human genes 0.000 description 3
- 102220049128 rs587784485 Human genes 0.000 description 3
- 102220033185 rs62646881 Human genes 0.000 description 3
- 102220001216 rs74315456 Human genes 0.000 description 3
- 102220180232 rs75680863 Human genes 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000112287 Bat coronavirus Species 0.000 description 2
- 241000008904 Betacoronavirus Species 0.000 description 2
- 241000711443 Bovine coronavirus Species 0.000 description 2
- 108700002856 Coronavirus Envelope Proteins Proteins 0.000 description 2
- 102220557633 DNA-directed RNA polymerase I subunit RPA12_Q14H_mutation Human genes 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000712902 Lassa mammarenavirus Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 241001292005 Nidovirales Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- 102220599417 Spindlin-1_G1219V_mutation Human genes 0.000 description 2
- 102220599401 Spindlin-1_H1101Y_mutation Human genes 0.000 description 2
- 102220599420 Spindlin-1_N501T_mutation Human genes 0.000 description 2
- 102220590625 Spindlin-1_P26S_mutation Human genes 0.000 description 2
- 102220599684 Spindlin-1_Q613H_mutation Human genes 0.000 description 2
- 102220590688 Spindlin-1_R102I_mutation Human genes 0.000 description 2
- 102220599655 Spindlin-1_S477N_mutation Human genes 0.000 description 2
- 102220590690 Spindlin-1_T76I_mutation Human genes 0.000 description 2
- 102220599418 Spindlin-1_V1176F_mutation Human genes 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000026502 entry into host cell Effects 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 108700021021 mRNA Vaccine Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000013639 protein trimer Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 102200155728 rs121918462 Human genes 0.000 description 2
- 102220282987 rs1555618704 Human genes 0.000 description 2
- 102200128238 rs201124247 Human genes 0.000 description 2
- 102220024392 rs267607495 Human genes 0.000 description 2
- 102220251923 rs778069675 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229940124954 vaccinia virus vaccine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- ABQGFYSYSCHJNB-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-(pyridin-2-yldisulfanyl)pentanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCSSC1=CC=CC=N1 ABQGFYSYSCHJNB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- UBDHSURDYAETAL-UHFFFAOYSA-N 8-aminonaphthalene-1,3,6-trisulfonic acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(N)=CC(S(O)(=O)=O)=CC2=C1 UBDHSURDYAETAL-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 1
- 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101000983970 Conus catus Alpha-conotoxin CIB Proteins 0.000 description 1
- 101000932768 Conus catus Alpha-conotoxin CIC Proteins 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 241000004175 Coronavirinae Species 0.000 description 1
- 108700003471 Coronavirus 3C Proteases Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241001461743 Deltacoronavirus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102220543270 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A_Y453F_mutation Human genes 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000008920 Gammacoronavirus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 1
- 102220609909 Homeobox protein VENTX_L21F_mutation Human genes 0.000 description 1
- 102220609970 Homeobox protein VENTX_V24M_mutation Human genes 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229940125583 Inovio COVID-19 vaccine Drugs 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102220498484 Leucine-rich repeat flightless-interacting protein 1_S68C_mutation Human genes 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000228636 Rhinolophus Species 0.000 description 1
- 102220616378 Rhombotin-1_D72H_mutation Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241001660014 Salmon pancreas disease virus Species 0.000 description 1
- 241001678561 Sarbecovirus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101000953879 Severe acute respiratory syndrome coronavirus Membrane protein Proteins 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 102220380137 c.155T>C Human genes 0.000 description 1
- 102220350260 c.223G>C Human genes 0.000 description 1
- 102200104762 c.437G>A Human genes 0.000 description 1
- 102200071735 c.524C>T Human genes 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102200139266 rs10490924 Human genes 0.000 description 1
- 102200035770 rs121908063 Human genes 0.000 description 1
- 102200078299 rs121908253 Human genes 0.000 description 1
- 102200109616 rs121909527 Human genes 0.000 description 1
- 102200081495 rs1341175303 Human genes 0.000 description 1
- 102220285822 rs1423724305 Human genes 0.000 description 1
- 102220052251 rs142554264 Human genes 0.000 description 1
- 102220246998 rs144776609 Human genes 0.000 description 1
- 102220066018 rs147551003 Human genes 0.000 description 1
- 102220089738 rs147911699 Human genes 0.000 description 1
- 102220103674 rs147911699 Human genes 0.000 description 1
- 102200072359 rs1805388 Human genes 0.000 description 1
- 102200004174 rs199473442 Human genes 0.000 description 1
- 102200161721 rs201073369 Human genes 0.000 description 1
- 102200051957 rs2472553 Human genes 0.000 description 1
- 102220214839 rs375401722 Human genes 0.000 description 1
- 102220141470 rs768764242 Human genes 0.000 description 1
- 102220392400 rs779540528 Human genes 0.000 description 1
- 102200067661 rs80359214 Human genes 0.000 description 1
- 102220088154 rs869025539 Human genes 0.000 description 1
- 102220181656 rs886053219 Human genes 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 244000309458 single stranded enveloped RNA virus Species 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
- C12N15/8636—Vaccina virus vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976913P | 2020-02-14 | 2020-02-14 | |
| US62/976,913 | 2020-02-14 | ||
| US202062977402P | 2020-02-16 | 2020-02-16 | |
| US62/977,402 | 2020-02-16 | ||
| US202062992710P | 2020-03-20 | 2020-03-20 | |
| US62/992,710 | 2020-03-20 | ||
| US202063026580P | 2020-05-18 | 2020-05-18 | |
| US63/026,580 | 2020-05-18 | ||
| PCT/US2021/018033 WO2021163622A1 (en) | 2020-02-14 | 2021-02-12 | Vaccines and uses thereof to induce an immune response to sars-cov2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3167052A1 true CA3167052A1 (en) | 2021-08-19 |
Family
ID=77292751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3167052A Pending CA3167052A1 (en) | 2020-02-14 | 2021-02-12 | Vaccines and uses thereof to induce an immune response to sars-cov2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220396810A1 (de) |
| EP (1) | EP4103231A4 (de) |
| JP (1) | JP2023513611A (de) |
| KR (1) | KR20220154114A (de) |
| CN (1) | CN115529817A (de) |
| AU (1) | AU2021220991A1 (de) |
| BR (1) | BR112022014884A2 (de) |
| CA (1) | CA3167052A1 (de) |
| IL (1) | IL295482A (de) |
| MX (1) | MX2022009962A (de) |
| TW (1) | TW202140794A (de) |
| WO (1) | WO2021163622A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
| TW202204622A (zh) * | 2020-04-09 | 2022-02-01 | 大陸商蘇州艾博生物科技有限公司 | 針對冠狀病毒之核酸疫苗 |
| JP2023528984A (ja) * | 2020-06-10 | 2023-07-06 | バヴァリアン・ノルディック・アクティーゼルスカブ | コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン |
| TW202212567A (zh) * | 2020-07-31 | 2022-04-01 | 公益財團法人東京都醫學總合研究所 | 重組牛痘病毒 |
| CA3205569A1 (en) | 2020-12-22 | 2022-06-30 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| KR20230031756A (ko) * | 2021-08-27 | 2023-03-07 | 한국과학기술원 | 신종 코로나바이러스 감염증 대응 예방 백신 조성물 |
| KR20240073046A (ko) * | 2021-10-07 | 2024-05-24 | 프레시젼 나노시스템스 유엘씨 | Rna 백신 지질 나노입자 |
| WO2023069461A2 (en) * | 2021-10-19 | 2023-04-27 | Vaxxinity, Inc. | Method for the prevention and treatment of coronavirus disease |
| WO2023092023A2 (en) * | 2021-11-17 | 2023-05-25 | City Of Hope | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) |
| WO2023200858A1 (en) * | 2022-04-13 | 2023-10-19 | The Trustees Of Columbia University In The City Of New York | Inhibitory peptides against coronaviruses |
| GB2624391A (en) * | 2022-11-15 | 2024-05-22 | Univ Cape Town | Recombinant LSDV vectored bovine coronavirus antigen constructs |
| WO2024118079A1 (en) * | 2022-12-01 | 2024-06-06 | Vaxxinity, Inc. | Method for the prevention and treatment of coronavirus disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9045727B2 (en) * | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| US7396914B2 (en) * | 2003-08-04 | 2008-07-08 | University Of Massachusetts | SARS nucleic acids, proteins, antibodies, and uses thereof |
| AU2005294129B2 (en) * | 2004-10-08 | 2010-12-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonymous codons |
| TWI526539B (zh) * | 2010-12-22 | 2016-03-21 | 苜蓿股份有限公司 | 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp |
| JP7150611B2 (ja) * | 2016-01-08 | 2022-10-11 | ジオバックス・インコーポレイテッド | 腫瘍関連抗原に対する免疫応答を誘起するための組成物及び方法 |
| WO2017121791A1 (en) * | 2016-01-12 | 2017-07-20 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Means and methods for treating hbv |
| WO2018170347A1 (en) * | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| MX2022010588A (es) * | 2020-02-26 | 2023-02-09 | Tonix Pharma Ltd | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. |
| US11130787B2 (en) * | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| EP3928789A1 (de) * | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene |
-
2021
- 2021-02-12 WO PCT/US2021/018033 patent/WO2021163622A1/en unknown
- 2021-02-12 MX MX2022009962A patent/MX2022009962A/es unknown
- 2021-02-12 IL IL295482A patent/IL295482A/en unknown
- 2021-02-12 CN CN202180015836.7A patent/CN115529817A/zh active Pending
- 2021-02-12 BR BR112022014884A patent/BR112022014884A2/pt unknown
- 2021-02-12 AU AU2021220991A patent/AU2021220991A1/en active Pending
- 2021-02-12 CA CA3167052A patent/CA3167052A1/en active Pending
- 2021-02-12 EP EP21754084.8A patent/EP4103231A4/de active Pending
- 2021-02-12 JP JP2022549163A patent/JP2023513611A/ja active Pending
- 2021-02-12 KR KR1020227031509A patent/KR20220154114A/ko unknown
- 2021-02-17 TW TW110105390A patent/TW202140794A/zh unknown
-
2022
- 2022-08-15 US US17/888,131 patent/US20220396810A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022009962A (es) | 2022-11-09 |
| EP4103231A1 (de) | 2022-12-21 |
| WO2021163622A1 (en) | 2021-08-19 |
| CN115529817A (zh) | 2022-12-27 |
| KR20220154114A (ko) | 2022-11-21 |
| TW202140794A (zh) | 2021-11-01 |
| EP4103231A4 (de) | 2024-03-27 |
| US20220396810A1 (en) | 2022-12-15 |
| BR112022014884A2 (pt) | 2022-10-11 |
| IL295482A (en) | 2022-10-01 |
| AU2021220991A1 (en) | 2022-09-29 |
| JP2023513611A (ja) | 2023-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220396810A1 (en) | Vaccines and uses thereof to induce an immune response to sars-cov2 | |
| JP7113924B2 (ja) | 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン | |
| US11028130B2 (en) | PR13.5 promoter for robust T-cell and antibody responses | |
| US5741492A (en) | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses | |
| ES2685124T3 (es) | Sistema de expresión de poxvirus | |
| ES2396376T3 (es) | Sitios intergénicos entre genes conservados en el genoma del virus vaccinia Ankara modificado (MVA) | |
| SA518400172B1 (ar) | لقاحات متعددة التكافؤ لفيروس السعار والفيروس التاجي | |
| US11896657B2 (en) | Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus glycoprotein (GP) and matrix protein (VP40) | |
| US11638750B2 (en) | Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein | |
| TW200810779A (en) | Recombinant vaccine against bluetongue virus | |
| WO2012048817A2 (en) | Recombinant modified vaccinia virus ankara influenza vaccine | |
| WO2019018501A1 (en) | COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE | |
| WO2007093133A1 (fr) | Vaccin contre le sars basé sur un vecteur du virus vaccinia réplicatif | |
| CA2814643A1 (en) | Recombinant vaccinia virus having hemagglutinin protein genes derived from novel influenza viruses | |
| AU2022368453A1 (en) | Chimeric betacoronavirus spike polypeptides | |
| US11274282B2 (en) | Vesicular stomatitis vectors encoding Crimean-Congo hemorrhagic fever antigen | |
| US20100034851A1 (en) | AIDS Vaccine Based on Replicative Vaccinia Virus Vector | |
| JP2010528603A (ja) | ネコ抗原のアライグマポックスウイルス発現遺伝子 | |
| WO2019145739A1 (en) | Lassa virus antigenic composition | |
| WO2024206243A1 (en) | Pan-betacoronavirus vaccines and uses thereof | |
| CN113227360A (zh) | 具有新型流感病毒来源的血凝素蛋白基因的DIs株来源的重组牛痘病毒 | |
| Gebreeziabher | Development of Dual Vaccines for the Control of Peste des Petits Ruminants and Capripox Infections of Small Ruminants | |
| AU7219800A (en) | Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |